Information Provided By: 
Fly News Breaks for October 21, 2015
VNDA
Oct 21, 2015 | 06:10 EDT
Brean Capital analyst Difei Yang started shares of Vanda Pharmaceuticals with a Buy rating and $20 price target. The stock looks undervalued given the growth potential of Hetlioz and lack of generic competition for Fanapt, the analyst contends.
News For VNDA From the Last 2 Days
VNDA
Apr 19, 2024 | 11:12 EDT
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Intra-Cellular Therapies... To see the rest of the story go to thefly.com. See Story Here
